Research Shows Stereotactic Radiosurgery for Metastatic Brain Tumors Improves Survival Rates for Patients Under 50

In a recent study published in the journal of the American Society for Radiation Oncology (ASTRO), researchers demonstrated the efficacy of stereotactic radiosurgery (SRS) in the treatment of brain metastases, or tumors that have spread from a primary tumor in another area of the body to the brain.

The study examined the survival rates of patients age 50 and younger who received only SRS in comparison to patients of the same age group who received both SRS and whole brain radiation therapy (WBRT). Researchers determined that the survival rate was improved by 13 percent for patients who received SRS alone, when compared to the other group. To read more details from the study, click here.

Columbus CyberKnife uses advanced CyberKnife® technology to treat brain metastases with SRS. CyberKnife treats tumors in the brain with highly focused radiation, while sparing healthy surrounding tissue. CyberKnife SRS offers brain tumor patients an aggressive treatment option with minimal disruption to normal activities. Typically, patients experience few to no side effects from treatment, which does not require surgery or sedation.

To find out if you or a loved one could be a candidate for CyberKnife treatment, contact our center.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.